A Phase III, double-blind, randomized, multinational trial to evaluate safety and immunogenicity of INNOVAX Recombinant Human Papillomavirus 9-valent (Types 6/11/16/18/31/33/45/52/58) Vaccine (Escherichia Coli) compared to GARDASIL®9 in a single-dose regimen in healthy girls and young women in Ghana and the Philippines
Operational feasibility of appropriate radical cure of plasmodium vivax with tafenoquine or primaquine after semi-quantitative G6PD testing in Ethiopia
Clinical evaluation of a point-of-care spectrophotometric test for detecting G6PD deficiency - NIL
100 项与 PATH Corp. 相关的临床结果
0 项与 PATH Corp. 相关的专利(医药)
100 项与 PATH Corp. 相关的药物交易
100 项与 PATH Corp. 相关的转化医学